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Abstract
I In nt tr ro od du uc ct ti io on n: :   Patients with implanted bioprostheses are at risk of structural dys-
function which results from the limited durability of biological valves. The aim
of this study was to analyse the mechanism of bioprosthesis degeneration and
to evaluate the usability of transthoracic and transoesophageal echocardiogra-
phy in determining the indications for reoperation in 117 patients with a bio-
prosthesis implanted before 65 years old.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The study comprised 117 consecutive patients (M – 27,
F – 90, age 48-74 years, 57.5 ±9.5 years) with a bioprosthesis implanted under
the age of 65, who were examined in accordance with the accepted protocol
and whose complete clinical and echocardiographic documentation was col-
lected. The scheduled echocardiographic examination was performed annually
from the 5 year after implantation of the bioprosthesis in patients with a valve
implanted over the age of 35 years and from the 1 year after bioprosthesis implan-
tation in patients with a prosthesis implanted at a younger age. Unscheduled
echocardiographic examinations were performed only on clinical indications.
R Re es su ul lt ts s: :   During the period under observation, due to degeneration of the bio-
prosthesis 76 patients were reoperated, including 62 patients with mitral bio-
prostheses. In 88.7% of patients with degeneration of mitral valve bioprosthe-
ses, regurgitation was observed. In 69% of patients with aortic bioprostheses,
valve dysfunction was the dominant mechanism of stenosis.
C Co on nc cl lu us si io on ns s: :   The most common mechanism of structural dysfunction of a mitral
bioprosthesis is regurgitation caused by prolapse or perforation of one of the
leaflets. Degeneration of an aortic bioprosthesis usually results in aortic steno-
sis. In cases of bioprosthesis degeneration connected with stenosis, transtho-
racic echocardiography was sufficient for the evaluation of valve dysfunction.
In the case of bioprosthesis dysfunction accompanied by regurgitation, tran-
soesophageal echocardiography was more informative to decide when the oper-
ation should be performed.
K Ke ey y   w wo or rd ds s: :   bioprosthesis, transthoracic echocardiography, transoesophageal
echocardiography, reoperation.
Introduction
Patients with implanted bioprostheses are at risk of structural dys-
function which results from the limited durability of biological valves. Dura-
C Co or rr re es sp po on nd di in ng g   a au ut th ho or r: :
Marek Maciejewski MD, PhD
Clinic of Cardiology
Institute of Cardiology
and Cardiac Surgery
Medical University of Lodz
1/3 Sterlinga St
91-425 Lodz, Poland
Phone/fax: +48 42 636 44 71
E-mail: marek56maciejewski@
gmail.com
Clinical research
1Department of Cardiology, Institute of Cardiology and Cardiac Surgery, 
Medical University of Lodz, Poland
2Department of Hypertension, Medical University of Lodz, Poland
3Department of Cardiac Surgery, Institute of Cardiology and Cardiac Surgery, 
Medical University of Lodz, Poland
S Su ub bm mi it tt te ed d: :   24 January 2011
A Ac cc ce ep pt te ed d: :   9 June 2011
Arch Med Sci 2011; 7, 6: 993-999
DOI: 10.5114/AOMS.2011.26611
Copyright ﾩ 2011 Termedia & Banach994 Arch Med Sci 6, December / 2011
Marek Maciejewski, Katarzyna Piestrzeniewicz, Agata Bielecka-Dabrowa, Andrzej Walczak
bility of this type of valve is dependent mainly on
the patient’s age at the time of prosthesis implan-
tation and its localization [1-3]. Clinical signs of arti-
ficial biological prosthetic valve dysfunction, result-
ing both from its damage and complications not
related to the valve itself, are similar. Diagnosis is
often possible after echocardiography, usually tran-
soesophageal, is performed. Structural dysfunction
of a bioprosthesis implanted in patients after 65
years of age, according to the majority of authors,
results from its mineralization and usually devel-
ops in the form of valve stenosis [4-6]. Our own
observations of a group of patients under the age
of 65 years with implanted bioprostheses indicate
a different mechanism of degeneration occurring
in these subjects. 
The aim of this study was to analyse the mech-
anism of bioprosthesis degeneration and to evalu-
ate the usability of thoracic and transoesophageal
echocardiography in the monitoring of the biologi-
cal valve degeneration process. 
Material and methods
The study comprised 117 consecutive patients
with a bioprosthesis implanted under the age of
65, who were examined between 1987 and 2009 in
accordance with the accepted protocol [7] (Table I),
and whose complete clinical and echocardiograph-
ic documentation was collected. In the study group
there were 27 men and 90 women. Mitral valves
were implanted in 79 patients, aortic valves in 23
patients, tricuspid valves in 2 patients and two arti-
ficial valves in 13 patients. A total of 130 biopros-
theses were implanted, including 122 bioprosthe-
ses from Carpentier-Edwards and 8 from other
manufacturers. The age of patients at the end of
observation ranged from 48 to 74 years (mean 57.5
±9.5 years). Twenty-three patients were in NYHA
functional class III at that time, the others in NYHA
functional class I-II. During the follow-up period, 
76 patients underwent a valve replacement because
of its degeneration, and 13 patients were reoperat-
ed because of infective endocarditis. Information
concerning the types of biological valves which
required exchange is shown in Table II. In order to
fulfil the aim of this study, 13 patients with infec-
tive endocarditis were excluded from further analy-
sis, and thus 104 patients, who did not differ demo-
graphically from the initially presented group of
patients with implanted bioprostheses, were sub-
jected to a final evaluation. 
S St tu ud dy y   p pr ro ot to oc co ol l   a ac cc co or rd di in ng g   t to o   E ES SC C   g gu ui id de el li in ne es s
The scheduled echocardiographic examination
was performed annually from the 5th year after
implantation of the bioprosthesis in patients with
a valve implanted over the age of 35 years and
from the 1st year after bioprosthesis implantation
in  patients  with  a prosthesis  implanted  at
a younger age. Unscheduled echocardiographic
examinations were performed only on clinical
A Ag ge e   [ [y ye ea ar rs s] ] M Me ea an n    57.5 ±9.6 
( (f fr ro om m- -t to o) ) (48-74)
S Se ex x M M( (% %) )/ /F F* * 27 (23)/90
M Mi it tr ra al l    n n ( (% %) ) 38 (32.5)
c co om mm mi is ss su ur ro ot to om my y
A Ag ge e   d du ur ri in ng g   v va al lv ve e    M Me ea an n    47.3 ±9.6 
r re ep pl la ac ce em me en nt t   [ [y ye ea ar rs s] ] ( (f fr ro om m- -t to o) ) (37-65)
T Ty yp pe e   o of f   b bi io op pr ro os st th he es si is s: :   
O On ne e   m mi it tr ra al l n n 79
O On ne e   a ao or rt ti ic c n n 23
O On ne e   t tr ri ic cu us sp pi id d n n 2
M Mi it tr ra al l   a an nd d   a ao or rt ti ic c          n n 13
T To ot ta al l       n n 130
T Ti im me e   f fr ro om m   p pr ro os st th he et ti ic c    M Me ea an n    121.5 ±4.0 
v va al lv ve e   i im mp pl la an nt ta at ti io on n ( (f fr ro om m- -t to o) ) (13-230)
[ [m mo on nt th hs s] ]
A At tr ri ia al l   f fi ib br ri il ll la at ti io on n n n ( (% %) ) 79 (67.5)
E Em mb bo ol li ic c   c co om mp pl li ic ca at ti io on ns s n n ( (% %) ) 8 (6.8)
R Re eo op pe er ra at ti io on ns s n n ( (% %) ) 89 (76.0)
S St tr ru uc ct tu ur ra al l   d dy ys sf fu un nc ct ti io on n n n ( (% %) ) 76 (65.0)
I In nf fe ec ct ti iv ve e   e en nd do oc ca ar rd di it ti is s n n ( (% %) ) 13 (11.0)
T Ta ab bl le e   I I. . Characteristics of the 117 patients with
implanted bioprostheses
M/F – male/female, n – number of patients
T Ty yp pe e   o of f   d dy ys sf fu un nc ct ti io on n    p pC C- -E E    p pe er ri iC C- -E E I I- -S S L LI IO OT TT TA A T To ot ta al l
Infective endocarditis n (%) 12 ––1 13 (14.6)
Bioprosthesis structural degeneration  n (%) 65 425 76 (85.4)
Stenosis n (%) 14 1–2 17 (22.4)*
Regurgitation n (%) 51 323 59 (77.6)*
Together 77 426 89
T Ta ab bl le e   I II I. .   Types of bioprostheses and types of their dysfunction in 89 reoperated patients
pC-E – porcine Carpentier-Edwards bioprosthesis, periC-E – pericardial Carpentier-Edwards bioprosthesis, I-S – Ionescu-Shiley, * percentage applies
to patients with structural bioprosthesis degeneration Arch Med Sci 6, December / 2011 995
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indications. All standard transthoracic and tran-
soesophageal projections were initially recorded
on Super-VHS videotape, and from 1998 on a dig-
ital carrier. Bioprosthesis degeneration was diag-
nosed when thickening of cusps with reduction
of their mobility and with an increase in the flow
speed through the valve or the occurrence or
increasing severity of valvular regurgitation were
observed [7]. 
During the transoesophageal examination par-
ticular attention was paid to disturbances in bio-
prosthesis cusp mobility, especially to their prolapse
or the presence of perforation. The mechanism of
bioprosthesis degeneration was evaluated on the
basis of transoesophageal examination performed
in 5 patients with an urgent indication and in the
remaining 99 patients because of abnormalities
suspicion in TTE. During this examination, the fre-
quency of thrombotic material occurrence in the
heart and the thoracic aorta and the presence of
perivalvular leak were also evaluated. The usabili-
ty of transthoracic and transoesophageal echocar-
diography in the recognition of bioprosthesis struc-
tural dysfunction and its mechanism was evaluated
on the basis of the intraoperative image. The analy-
sis of consecutive echocardiograms of patients
allowed for the evaluation of the progress of bio-
prosthesis structural dysfunction depending on its
mechanism [7]. 
Results 
The first, scheduled echocardiographic exami-
nation performed in patients with normal, accord-
ing to clinical assessment, function of the artificial
valve demonstrated the presence of insignificant
structural regurgitation in 35 patients (30%) and
suggested thickening of the valve leaflets in 12
patients. Until the completion of studies, on aver-
age, 121.5 months after bioprosthesis implantation,
76 patients were reoperated. The remaining 28
patients were under clinical and echocardiograph-
ic monitoring. The results presented below apply to
preoperative transthoracic and transoesophageal
echocardiograms  of  reoperated  patients  and
echocardiograms made in the last year of observa-
tion of patients without valve replacement. 
T Tr ra an ns st th ho or ra ac ci ic c   s st tu ud dy y
Morphological  assessment  of  bioprosthesis
leaflets showed their thickening in 32 patients and
in 32 patients prolapse or perforation of the bio-
logical valve was observed. In the remaining 40
patients the morphology of leaflets was assessed
as normal. Functional assessment showed signifi-
cant valve stenosis in 19 patients, its significant
regurgitation in 24 patients and normal function of
the valvular prosthesis in the remaining 61 patients
(Figure 1). 
F Fi ig gu ur re e   1 1. . Results of transthoracic (TTE) and transoesophageal (TEE) echocardiography in 104 patients with implant-
ed bioprostheses
*Also non-significant regurgitation or stenosis, **patients with significant mitral regurgitation assessed in transthoracic echocardiog-
raphy as non-significant
TTE, n = 104
TEE, n = 104
Morphology evaluation of the leaflets 
Normal
Thickening/prolapse or 
perforation of the leaflet 
Stenosis orcombined 
valve defect
Normal*
Significant 
regurgitation
32/32 19 61 24
19 26/59
Including reoperated: 17/59
17 28
Additional “findings”, n = 9
Reoperation, n = 76
59
Functional assessment
40
n = 35**996 Arch Med Sci 6, December / 2011
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T Tr ra an ns so oe es so op ph ha ag ge ea al l   s st tu ud dy y
Morphological  assessment  of  bioprosthesis
leaflets demonstrated their thickening in 26 pa-
tients.  Thickening  of  leaflets  observed  during
transthoracic examination was not confirmed in the
remaining 6 patients. Prolapse or perforation of bio-
prosthesis leaflets was reported in a total of 59
patients, including 32 patients with the diagnosis
made on the basis of transthoracic examination.
No morphological changes of leaflets were seen in
19 patients (Figure 1). 
Functional assessment confirmed the presence
of stenosis in 17 out of 19 patients with such a diag-
nosis made on the basis of transthoracic examina-
tion (Figure 2) and revealed the presence of signif-
icant  regurgitation  in  59  patients  (Figure  3),
including 24 subjects with such a diagnosis made
on the basis of transthoracic examination. In the
remaining 28 patients bioprosthesis function was
F Fi ig gu ur re e   2 2. . Patient, 63 years old, male, class III NYHA. Mitral pericardial Carpentier-Edwards bioprosthesis implanted
12 years ago. Transthoracic echocardiography: A A1 1 – parasternal long axis view: extensive calcification of the valve
leaflets with a significant reduction of their mobility (arrows). A A2 2 – parasternal long axis view: improper angle
between the axis of the valve and left ventricular outflow tract. B B1 1 and B B2 2 – apical 4-chamber view: maintained suf-
ficient mobility of one of the leaflets (arrow). C C and D D – apical 4-chamber view (continuous wave Doppler echocar-
diography): haemodynamically significant combined mitral valve defect
A A1 1 A A2 2
B B1 1 B B2 2
C C D DArch Med Sci 6, December / 2011 997
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assessed as normal. Moreover, during the transoe-
sophageal examination, potential embolic sources
were found in 9 patients (8.6%), including 6 pa  -
tients with thrombotic material in a single location
and 3 patients with multiple embolic sources. 
In 3 pa  tients, thrombus was found on the ring of
the bioprosthesis, in 5 patients it was present in
the left atrium or its auricle, and in 4 patients com-
plex atherosclerotic plaques in the thoracic aorta
were reported. The presence of spontaneous echo
contrast was observed in the left atrium of 55
patients, and in the aorta of 2 patients. Haemody-
namically insignificant paravalvular leak was found
in 5 patients. 
I In nd di ic ca at ti io on ns s   f fo or r   r re eo op pe er ra at ti io on n
Seventy-six patients were qualified for reopera-
tion. In all patients intraoperative assessment con-
firmed the diagnosis made on the basis of tran-
soesophageal examination. Valve regurgitation
resulting from prolapse of the leaflet or its perfo-
ration was the reason for reoperation in 59 patients
(77.6%), while stenosis or stenosis with valve regur-
gitation  was  the  reason  in  the  remaining  17
patients. Among 62 patients reoperated due to
structural dysfunction of a mitral bioprosthesis,
dominant regurgitation was seen in 55 patients
(88.7%). Among 13 patients with an aortic biopros-
thesis, stenosis was the predominant mechanism
of dysfunction (9 patients, 69%). 
T Th he e   c ch ho oi ic ce e   o of f   r re eo op pe er ra at ti io on n   d da at te e
The analysis of the progression of bioprosthesis
structural dysfunction revealed rapid acceleration
of this process in cases when regurgitation was the
dominant mechanism of degeneration. Forty-five
patients (76.3%) with bioprosthesis regurgitation
reported for the first time or with worsening of
regurgitation required reoperation during the first
year, usually during the first 6 months, since the
first detection of a dicrotic wave. Worsening of
regurgitation or the appearance of clinical symp-
toms (increase in the degree of heart failure) was
the direct reason for reoperation. Five patients were
reoperated for urgent indications. If any feature of
valvular stenosis was observed, the progression of
structural dysfunction was usually slow. Ten out of
13 patients with stenosis as the predominant 
mechanism of degeneration required reoperation
≥ 2 years after the first detection of features of
structural dysfunction. 
Discussion 
Structural dysfunction of the bioprosthesis was
the most common reason for reoperation in our
study (76 patients – 39.2%). Also, other authors
indicate that bioprosthesis degeneration is the most
frequent reason for valvular reoperation [8-10]. The
necessity of reoperation of every patient whose sur-
vival is long results from the limited durability of
the bioprosthesis [11], especially in patients oper-
ated on under the age of 60-65 years [10, 12]. Good
long-term results of bioprosthesis implantation in
older patients are well known [13-15]. Long-term
results of implantation of currently available bio-
prostheses are comparable [16, 17]. Very good
results of bioprosthesis implantation in patients
who underwent surgery under the age of 60 years
and were followed for over 20 years were present-
ed by Ruel et al. [18]. 
This study comprises only patients with bio-
prostheses implanted under the age of 65 years.
Average durability of bioprostheses was about 10
years. These observations do not differ from earli-
er reports [19, 20]. Van Doorn et al. [21] reported
rapid increase in the frequency of degeneration of
the standard Carpentier-Edwards bioprosthesis
from the 7th year after its implantation. Higher dura-
bility of some bioprosthesis models was described
F Fi ig gu ur re e   3 3. . Patient, 67 years old, male, class III NYHA. Mitral porcine Carpentier-Edwards bioprosthesis implanted 13 years
ago. Transoesophageal echocardiography: A A – mid-oesophageal view 53° – bioprosthetic valve, B B   – mid-oesophageal
view 97 degrees (colour flow Doppler) – multidirectional mitral regurgitation connected with valve prolapse
A A B B998 Arch Med Sci 6, December / 2011
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in several reports [12, 18]. The impact of the small
size of the aortic bioprosthesis on its earlier degen-
eration is also known [22]. 
In our study, valvular regurgitation was a direct
indication for reoperation in most patients (77.6%)
and mitral valve regurgitation was the dominant
mechanism of dysfunction in 88.7% of patients.
Other authors reported that regurgitation of the
mitral bioprosthesis was the dominant mechanism
of dysfunction only in 30% of patients [23, 24].
These differences may result from the demographic
dissimilarity of study group of patients as well as
from the rheumatic aetiology of operated heart
defects presented in this paper. Perennial course of
mitral stenosis and significant enlargement of the
left atrium resulted in that the axis of the implant-
ed bioprosthesis usually was not perpendicular to
the axis of the left ventricle (Figure 2). This could
lead to a local change of haemodynamic conditions
and functions of particular bioprosthesis leaflets.
The most common indication for reoperation of
patients with implanted aortic valves was stenosis
or complex defect with a predominant stenosis,
which is consistent with previous reports [25, 26]. 
The usability of transthoracic echocardiography
in the diagnosis and in the assessment of the sever-
ity of bioprosthesis structural dysfunction was lim-
ited. In our study, morphological assessment of
leaflets was demonstrated to over-recognize the
thickening of bioprosthesis leaflets but, on the oth-
er hand, it failed to detect bioprosthesis prolapse
in some patients. In the functional assessment,
transthoracic echocardiography was sufficient for
the identification and evaluation of bioprosthesis
stenosis degree; however, specific assessment of
the degree of mitral valve regurgitation by this
method was possible only in 41% of patients. In the
remaining patients, the dicrotic wave through the
bioprosthesis was visualized during transthoracic
examination, but it was assessed as irrelevant.
These patients derived the greatest benefit from
the transoesophageal examination. These obser-
vations indicated serious limitations of transtho-
racic echocardiography in the diagnosis of biopros-
thesis  structural  dysfunction  accompanied  by
regurgitation due to leaflet prolapse. 
In patients with detected potential sources of
systemic embolism, atrial fibrillation, symptoms of
heart failure (mainly NYHA functional class III) and
advanced age (usually over 65 years) were more
frequent. 
Bioprosthesis structural dysfunction does not
lead to the increase in perioperative risk, if reoper-
ation is carried out as scheduled [8, 12, 18]. In this
study, only 5 patients were reoperated for urgent
indications, all due to a sharp worsening of circu-
latory function resulting from mitral bioprosthesis
regurgitation. Rapid deterioration in clinical state
of patients with bioprosthesis degeneration accom-
panied by its regurgitation can be explained by the
type of valve leaflet damage. Perforation or leaflet
prolapse often accompanied by its “flail” movement
results in hemodynamic consequences compara-
ble to those of acute mitral regurgitation. The
remaining 71 patients were reoperated according
to schedule. These patients were monitored every
3-6 months during the final year before the reop-
eration. The percentage of patients reoperated
according to the schedule did not differ from that
reported by other authors [11, 12, 18, 21]. 
In conclusion, the most common mechanism of
structural dysfunction of a mitral bioprosthesis is
regurgitation caused by prolapse or perforation of
one of the leaflets. Degeneration of an aortic bio-
prosthesis  usually  results  in  aortic  stenosis.
Transthoracic echocardiography is sufficient for the
periodic monitoring of patients with implanted bio-
prostheses. Transoesophageal echocardiography is
more accurate for patients with mitral bioprosthe-
sis dysfunction accompanied by regurgitation. There
is a group of patients aged 65 years with implant-
ed bioprostheses, chronic atrial fibrillation and
chronic heart failure, in whom transoesophageal
echocardiography can give relevant information
regarding the left atrial auricle and thoracic aorta,
in the context of the scheduled reoperation.
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